RU2012105641A - Фолатнацеленные диагностические средства и лечение - Google Patents

Фолатнацеленные диагностические средства и лечение Download PDF

Info

Publication number
RU2012105641A
RU2012105641A RU2012105641/15A RU2012105641A RU2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641/15 A RU2012105641/15 A RU 2012105641/15A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A
Authority
RU
Russia
Prior art keywords
tumor
patient
administering
folate receptors
clinical benefit
Prior art date
Application number
RU2012105641/15A
Other languages
English (en)
Russian (ru)
Inventor
Кристофер Пол Лимон
Ричард МЕССМЭНН
Дэвид МОРГЕНСТЕРН
Original Assignee
Индосайт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индосайт, Инк. filed Critical Индосайт, Инк.
Publication of RU2012105641A publication Critical patent/RU2012105641A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012105641/15A 2009-07-31 2010-07-30 Фолатнацеленные диагностические средства и лечение RU2012105641A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US61/230,595 2009-07-31
US34644410P 2010-05-19 2010-05-19
US61/346,444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351,022 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Publications (1)

Publication Number Publication Date
RU2012105641A true RU2012105641A (ru) 2013-09-10

Family

ID=43529728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012105641/15A RU2012105641A (ru) 2009-07-31 2010-07-30 Фолатнацеленные диагностические средства и лечение

Country Status (13)

Country Link
US (2) US20120128587A1 (enExample)
EP (1) EP2460013A4 (enExample)
JP (1) JP2013501224A (enExample)
KR (1) KR20120050462A (enExample)
CN (2) CN104857534A (enExample)
AU (1) AU2010278734A1 (enExample)
BR (1) BR112012002064A2 (enExample)
CA (1) CA2769754A1 (enExample)
IL (1) IL217744A0 (enExample)
IN (1) IN2012DN01708A (enExample)
NZ (1) NZ598145A (enExample)
RU (1) RU2012105641A (enExample)
WO (1) WO2011014821A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US8987281B2 (en) 2010-11-12 2015-03-24 Endocyte, Inc. Methods of treating cancer
CN103607891A (zh) * 2011-04-12 2014-02-26 恩多塞特公司 固体药用组合物
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
WO2015055796A1 (en) 2013-10-16 2015-04-23 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
EP3574924B1 (en) 2013-11-19 2021-01-06 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20170368208A1 (en) * 2015-01-11 2017-12-28 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3600430A4 (en) * 2016-03-29 2020-12-30 Endocyte, Inc. FOLATE CONJUGATE FOR USE IN TARGETING TUMOR-ASSOCIATED MACROPHAGES
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN121337736A (zh) * 2025-12-16 2026-01-16 临沂市人民医院 多柔比星与免疫调节剂共载脂质体的制备及其协同抗肿瘤用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601332B2 (en) * 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
JP5243041B2 (ja) * 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
CA2592302C (en) * 2004-12-23 2013-10-29 Purdue Research Foundation Positron emission tomography imaging method
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
DE602006012816D1 (de) * 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MX2009004555A (es) * 2006-10-25 2009-05-11 Schering Corp Metodos de tratamiento de cancer de ovario.
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos

Also Published As

Publication number Publication date
KR20120050462A (ko) 2012-05-18
US20140140925A1 (en) 2014-05-22
IN2012DN01708A (enExample) 2015-06-05
BR112012002064A2 (pt) 2017-05-09
IL217744A0 (en) 2012-03-29
EP2460013A1 (en) 2012-06-06
CA2769754A1 (en) 2011-02-03
EP2460013A4 (en) 2013-04-03
US20120128587A1 (en) 2012-05-24
WO2011014821A1 (en) 2011-02-03
CN104857534A (zh) 2015-08-26
AU2010278734A1 (en) 2012-02-23
NZ598145A (en) 2014-10-31
JP2013501224A (ja) 2013-01-10
CN102549434A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
Wang et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Shimomura et al. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors
Mégalizzi et al. 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs
US20250325553A1 (en) Methods of treating cancer
Infante et al. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
US20140140925A1 (en) Folate-targeted diagnostics and treatment
JP2013501224A5 (enExample)
Wagner et al. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
Isambert et al. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase
Kaartinen et al. Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogs
Novello et al. Early Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer Assessed by [18F]-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography
Gilbert et al. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck
KR20180082428A (ko) 성장 호르몬 결핍의 검출 및 치료
Maino et al. Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface: A prospective comparison study of ultrasound‐guided vs. blind refill technique
JP2018538370A (ja) デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用
JP2021531330A (ja) 組合せ療法を使用してがんを治療する方法
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
Huang et al. Toxic myelitis and arachnoiditis after intrathecal delivery of bupivacaine via an implanted drug delivery system: case report and review of the literature
Sullivan et al. Treatments for severe psoriasis
CN116726182A (zh) 西奥罗尼联合抗代谢化疗药物治疗乳腺癌的用途
ES3024982T3 (en) Injection containing p-boronophenylalanine
Li et al. Pharmacokinetics of Agelastatin A in the central nervous system
Apfelbaum et al. LGG-02. Elucidating the role of fgfr1 alterations in pediatric gliomas
Linton-Romir et al. HASH (0x55d594cfd2b8)
Mohan et al. 67P Efficacy and safety of trastuzumab biosimilar in HER2+ ve metastatic breast cancer: A multicenter phase III study

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160126